Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea flag South Korea · Delayed Price · Currency is KRW
482,500
-26,500 (-5.21%)
Last updated: Aug 31, 2026, 1:54 PM KST

Hanmi Pharm. Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,655,4791,547,5311,495,5021,490,8871,331,5471,203,186
Other Revenue
-0-0---0-
1,655,4791,547,5311,495,5021,490,8871,331,5471,203,186
Revenue Growth
12.93%3.48%0.31%11.97%10.67%11.83%
Cost of Revenue
668,906663,124678,465661,638612,994570,433
Gross Profit
986,573884,407817,037829,249718,553632,752
Selling, General & Admin
447,974430,773421,960426,789406,146361,309
Research & Development
215,516195,834178,891181,769154,317146,027
Operating Expenses
710,335660,536604,526604,364564,657507,336
Operating Income
276,237223,870212,511224,885153,896125,416
Interest Expense
-14,350-16,986-24,374-28,508-22,647-16,577
Interest & Investment Income
9,5687,2665,6664,6187,8565,722
Earnings From Equity Investments
-19.22-7.45-9.21,258-8,537-4.02
Currency Exchange Gain (Loss)
16,2891,4349,3181,039-2,64113.07
Other Non Operating Income (Expenses)
-3,321-3,949-29,309-4,571-3,620-9,277
EBT Excluding Unusual Items
284,405211,628173,802198,721124,308105,293
Gain (Loss) on Sale of Investments
4,9454,762-87.922,63047.09-
Gain (Loss) on Sale of Assets
8.34101.227.741,769451.65-1,062
Asset Writedown
-3,088-3,013-2,488-9,153-3,794-535.2
Pretax Income
286,270213,478171,254193,967121,013103,697
Income Tax Expense
51,63526,34230,82328,60119,45422,218
Earnings From Continuing Operations
234,635187,136140,431165,366101,55881,478
Minority Interest in Earnings
-17,590-17,581-19,116-19,135-18,766-14,453
Net Income
217,045169,554121,315146,23182,79267,025
Net Income to Common
217,045169,554121,315146,23182,79267,025
Net Income Growth
102.18%39.76%-17.04%76.63%23.52%460.45%
Shares Outstanding (Basic)
131313131313
Shares Outstanding (Diluted)
131313131313
Shares Change
0.10%0.07%-0.08%-0.09%-0.12%-0.11%
EPS (Basic)
17111.7313371.579566.8311522.126517.335269.87
EPS (Diluted)
17099.5413362.009566.8311522.126517.335269.87
EPS Growth
101.96%39.67%-16.97%76.79%23.67%461.07%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
216,378130,048154,226189,186131,890181,974
Free Cash Flow Per Share
17047.1610248.7712162.1314906.6710382.3714307.73
Dividend Per Share
2000.0002000.000----
Dividend Growth
------
Gross Margin
59.59%57.15%54.63%55.62%53.96%52.59%
Operating Margin
16.69%14.47%14.21%15.08%11.56%10.42%
Profit Margin
13.11%10.96%8.11%9.81%6.22%5.57%
Free Cash Flow Margin
13.07%8.40%10.31%12.69%9.90%15.12%
EBITDA
375,897322,679309,842323,339250,738214,502
EBITDA Margin
22.71%20.85%20.72%21.69%18.83%17.83%
D&A For EBITDA
99,66098,80997,33198,45496,84289,086
EBIT
276,237223,870212,511224,885153,896125,416
EBIT Margin
16.69%14.47%14.21%15.08%11.56%10.42%
Effective Tax Rate
18.04%12.34%18.00%14.74%16.08%21.43%
Advertising Expenses
-73,81778,78976,03472,62762,201